Chong Kun Dang is working to accelerate the expansion of its diabetes treatment portfolio.

In addition to its own ‘Duvie (lobeglitazone),’ the company received approval for diabetes combination drugs that contain 'Januvia (sitagliptin),’ which it had acquired rights for in Korea. The release of such combination drugs is considered the company’s strategy to preoccupy the market before the patent expiry of Januvia.

According to industry sources on the 12th, Chong Kung Dang received approval for its Duvie Tab from the Ministry of Food and Drug Safety on the 9th. The drug is a combination between sitagliptin and lobeglitazone.

The company had received approval for Duvie,